Azenta to sell B Medical Systems for $63 million
The agreement to sell B Medical Systems marks a major step forward in simplifying the portfolio to prioritize our core capabilities with the highest strategic impact
The agreement to sell B Medical Systems marks a major step forward in simplifying the portfolio to prioritize our core capabilities with the highest strategic impact
Experts warn that illegal products may be fake, contaminated, incorrectly dosed, or contain powerful unlisted ingredients
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
The partnership also sets the stage for broader collaboration on rare disease treatments
The plant is expected to enhance regional supply capabilities
The study met its primary endpoint with flying colors
Subscribe To Our Newsletter & Stay Updated